The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance

Detalhes bibliográficos
Autor(a) principal: Ferreira da Silva, Renato
Data de Publicação: 2022
Outros Autores: Macedo, Mário, Conceição, Jaime
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.23882/rmd.22090
Resumo: The disease caused by the new SARS-CoV-2 virus (COVID-19) was first reported in December 2019 in Wuhan, China, and subsequently it spread throughout the world.On March 2, 2020, the first two cases of COVID-19 were confirmed in Portuguese territory, with the first death to be registered two weeks later, on March 16. Thereafter, a wide and variable set of sanitary measures were applied, as well as the publication of norms and guidelines by the Directorate-General of Health (DGS) and by the National Authority of Medicines and Health Products, I.P. (INFARMED). Later, on December 27, 2020, the first vaccine against COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer) was administered at the University Hospital Centre of São João, in Porto, marking the beginning of the defined vaccination plan by the task-force and the involvement of different health professionals.Pharmacovigilance of vaccines against COVID-19 is an area of ​​enormous importance, through the generation of real-world evidence on post-marketing safety and effectiveness. The Pharmacovigilance Systems are responsible for receiving, validating, analysing, requesting additional data, codifying and collaborating in the attribution of causality to all suspected adverse reactions.The aim of this article is to portray the COVID-19 pandemic in Portugal, with regard to its evolution, vaccination plan and Pharmacovigilance activities. Additionally, the issue is articulated with the international reality, highlighting the main measures, stakeholders and impact on public health.
id RCAP_a57dc04c07903d2b2dcdeeb7b6dd44ab
oai_identifier_str oai:ojs2.revistamultidisciplinar.com:article/90
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The COVID-19 pandemic in Portugal: Evolution, Vaccination and PharmacovigilanceA pandemia de COVID-19 em Portugal: Evolução, Vacinação e FarmacovigilânciaPandemiaCOVID-19PortugalVacinaçãoFarmacovigilânciaPandemicCOVID-19PortugalVaccinationPharmacovigilanceThe disease caused by the new SARS-CoV-2 virus (COVID-19) was first reported in December 2019 in Wuhan, China, and subsequently it spread throughout the world.On March 2, 2020, the first two cases of COVID-19 were confirmed in Portuguese territory, with the first death to be registered two weeks later, on March 16. Thereafter, a wide and variable set of sanitary measures were applied, as well as the publication of norms and guidelines by the Directorate-General of Health (DGS) and by the National Authority of Medicines and Health Products, I.P. (INFARMED). Later, on December 27, 2020, the first vaccine against COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer) was administered at the University Hospital Centre of São João, in Porto, marking the beginning of the defined vaccination plan by the task-force and the involvement of different health professionals.Pharmacovigilance of vaccines against COVID-19 is an area of ​​enormous importance, through the generation of real-world evidence on post-marketing safety and effectiveness. The Pharmacovigilance Systems are responsible for receiving, validating, analysing, requesting additional data, codifying and collaborating in the attribution of causality to all suspected adverse reactions.The aim of this article is to portray the COVID-19 pandemic in Portugal, with regard to its evolution, vaccination plan and Pharmacovigilance activities. Additionally, the issue is articulated with the international reality, highlighting the main measures, stakeholders and impact on public health.A doença provocada pelo novo vírus SARS-CoV-2 (COVID-19) foi relatada pela primeira vez em dezembro de 2019, em Wuhan, China, e posteriormente disseminou-se por todo o mundo.A 2 de março de 2020, foram confirmados os primeiros dois casos de COVID-19 em território português, com a primeira morte a ser registada duas semanas depois, a 16 de março. Daí em diante, um conjunto alargado e variável de medidas sanitárias foram aplicadas, assim como a publicação de normas e orientações pela Direção-Geral da Saúde (DGS) e pela Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (INFARMED). Posteriormente, a 27 de dezembro de 2020, foi administrada a primeira vacina contra a COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer), no Centro Hospitalar Universitário de São João, no Porto, marcando o início do plano de vacinação definido pela task-force e o envolvimento dos diversos profissionais de saúde.A Farmacovigilância das vacinas contra a COVID-19 constitui uma área de enorme importância, através da geração de evidência de mundo real sobre a segurança e efetividade pós-comercialização. Os Sistemas de Farmacovigilância têm a responsabilidade de rececionar, validar, analisar, solicitar dados adicionais, codificar e colaborar na imputação de causalidade de todas as suspeitas de reações adversas.Este artigo retrata a pandemia de COVID-19 em Portugal, no que concerne à sua evolução, plano de vacinação e atividades de Farmacovigilância. Adicionalmente, articula-se o tema com a realidade internacional, evidenciando-se as principais medidas, intervenientes e impacto na saúde pública.NMd, Núcleo Multidisiplinar2022-02-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdftext/htmlhttps://doi.org/10.23882/rmd.22090https://doi.org/10.23882/rmd.22090Multidisciplinary Journal; Vol. 4 No. 2 (2022): History of Science and Pandemics; 135-154RevistaMultidisciplinar; Vol. 4 Núm. 2 (2022): História da Ciência e as Pandemias; 135-154Revue Multidisciplinaire; Vol. 4 No 2 (2022): História da Ciência e as Pandemias; 135-154RevistaMultidisciplinar; Vol. 4 N.º 2 (2022): História da Ciência e as Pandemias; 135-1542184-549210.23882/rmd.v4n2reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revistamultidisciplinar.com/index.php/oj/article/view/90https://revistamultidisciplinar.com/index.php/oj/article/view/90/120https://revistamultidisciplinar.com/index.php/oj/article/view/90/128Direitos de Autor (c) 2022 Renato Ferreira da Silva, Mário Macedo, Jaime Conceiçãoinfo:eu-repo/semantics/openAccessFerreira da Silva, RenatoMacedo, MárioConceição, Jaime2022-12-31T07:00:28Zoai:ojs2.revistamultidisciplinar.com:article/90Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:48:33.670089Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
A pandemia de COVID-19 em Portugal: Evolução, Vacinação e Farmacovigilância
title The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
spellingShingle The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
Ferreira da Silva, Renato
Pandemia
COVID-19
Portugal
Vacinação
Farmacovigilância
Pandemic
COVID-19
Portugal
Vaccination
Pharmacovigilance
title_short The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
title_full The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
title_fullStr The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
title_full_unstemmed The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
title_sort The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
author Ferreira da Silva, Renato
author_facet Ferreira da Silva, Renato
Macedo, Mário
Conceição, Jaime
author_role author
author2 Macedo, Mário
Conceição, Jaime
author2_role author
author
dc.contributor.author.fl_str_mv Ferreira da Silva, Renato
Macedo, Mário
Conceição, Jaime
dc.subject.por.fl_str_mv Pandemia
COVID-19
Portugal
Vacinação
Farmacovigilância
Pandemic
COVID-19
Portugal
Vaccination
Pharmacovigilance
topic Pandemia
COVID-19
Portugal
Vacinação
Farmacovigilância
Pandemic
COVID-19
Portugal
Vaccination
Pharmacovigilance
description The disease caused by the new SARS-CoV-2 virus (COVID-19) was first reported in December 2019 in Wuhan, China, and subsequently it spread throughout the world.On March 2, 2020, the first two cases of COVID-19 were confirmed in Portuguese territory, with the first death to be registered two weeks later, on March 16. Thereafter, a wide and variable set of sanitary measures were applied, as well as the publication of norms and guidelines by the Directorate-General of Health (DGS) and by the National Authority of Medicines and Health Products, I.P. (INFARMED). Later, on December 27, 2020, the first vaccine against COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer) was administered at the University Hospital Centre of São João, in Porto, marking the beginning of the defined vaccination plan by the task-force and the involvement of different health professionals.Pharmacovigilance of vaccines against COVID-19 is an area of ​​enormous importance, through the generation of real-world evidence on post-marketing safety and effectiveness. The Pharmacovigilance Systems are responsible for receiving, validating, analysing, requesting additional data, codifying and collaborating in the attribution of causality to all suspected adverse reactions.The aim of this article is to portray the COVID-19 pandemic in Portugal, with regard to its evolution, vaccination plan and Pharmacovigilance activities. Additionally, the issue is articulated with the international reality, highlighting the main measures, stakeholders and impact on public health.
publishDate 2022
dc.date.none.fl_str_mv 2022-02-20
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.23882/rmd.22090
https://doi.org/10.23882/rmd.22090
url https://doi.org/10.23882/rmd.22090
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revistamultidisciplinar.com/index.php/oj/article/view/90
https://revistamultidisciplinar.com/index.php/oj/article/view/90/120
https://revistamultidisciplinar.com/index.php/oj/article/view/90/128
dc.rights.driver.fl_str_mv Direitos de Autor (c) 2022 Renato Ferreira da Silva, Mário Macedo, Jaime Conceição
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos de Autor (c) 2022 Renato Ferreira da Silva, Mário Macedo, Jaime Conceição
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/html
dc.publisher.none.fl_str_mv NMd, Núcleo Multidisiplinar
publisher.none.fl_str_mv NMd, Núcleo Multidisiplinar
dc.source.none.fl_str_mv Multidisciplinary Journal; Vol. 4 No. 2 (2022): History of Science and Pandemics; 135-154
RevistaMultidisciplinar; Vol. 4 Núm. 2 (2022): História da Ciência e as Pandemias; 135-154
Revue Multidisciplinaire; Vol. 4 No 2 (2022): História da Ciência e as Pandemias; 135-154
RevistaMultidisciplinar; Vol. 4 N.º 2 (2022): História da Ciência e as Pandemias; 135-154
2184-5492
10.23882/rmd.v4n2
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130351630548992